CCS
BHVN icon

Concentric Capital Strategies’s Biohaven BHVN Stock Holding History

Concentric Capital Strategies’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,912
Closed -$816K – 297
2024
Q1 		$816K Buy
+14,912
New +$738K 0.05% 252

Other funds holding BHVN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Concentric Capital Strategies's BHVN Position: Q2 2024 in Review

Concentric Capital Strategies sold out of Biohaven (BHVN) in Q2 2024, closing a stake of 14,912 shares — an estimated $816K sold.

Concentric Capital Strategies first reported a position in BHVN in Q1 2024 and held it in 1 quarter. The position peaked at $816K in Q1 2024. 225 funds tracked by Wall St. Rank hold BHVN as of Q2 2024.

  • Concentric Capital Strategies reported no remaining Biohaven position as of Q2 2024 after selling out during the quarter.
  • Concentric Capital Strategies sold 14,912 Biohaven shares in Q2 2024, an estimated $816K.
  • Concentric Capital Strategies first reported a position in Biohaven in Q1 2024 and held it in 1 quarter.
  • Concentric Capital Strategies's Biohaven position peaked at $816K in Q1 2024.
  • 225 funds tracked by Wall St. Rank held Biohaven as of Q2 2024.

Based on Concentric Capital Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.